Neurol India Home 

Year : 2021  |  Volume : 69  |  Issue : 7  |  Page : 98--104

Emerging Targets for Migraine Treatment

David Moreno-Ajona1, María Dolores Villar-Martínez1, Peter James Goadsby2 
1 Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
2 NIHR-Wellcome Trust King's Clinical Research Facility/SLaM Biomedical Research Centre, King's College Hospital, London, United Kingdom; Department of Neurology, University of California, Los Angeles, Los Angeles CA USA

Correspondence Address:
Dr. Peter James Goadsby
Wellcome Foundation Building, King's College Hospital, London SE5 9PJ

Background: While understanding the pathophysiology of migraine has led to CGRP-based treatments, other potential targets have also been implicated in migraine. Objectives: To catalog new promising targets for the treatment of migraine. Methods: We completed a literature review focusing on 5HT1F, PACAP, melatonin, and orexins. Results: The 5HT1F receptor agonist lasmiditan, following two positive randomized placebo-controlled trials, was FDA-approved for the acute treatment of migraine. PACAP-38 has shown analogous evidence to what was obtained for CGRP with its localization in key structures, provocation tests, and positive studies when antagonizing its receptor in animal models, although a PAC-1 receptor monoclonal antibody study was negative. Melatonin has undergone several randomized controlled trials showing a positive trend. Filorexant is the only dual orexin receptor antagonist, which was tested in humans with negative results. Conclusions: Further and ongoing studies will determine the utility of these new therapies with lasmiditan and melatonin having demonstrated efficacy for the treatment of migraine.

How to cite this article:
Moreno-Ajona D, Villar-Martínez MD, Goadsby PJ. Emerging Targets for Migraine Treatment.Neurol India 2021;69:98-104

How to cite this URL:
Moreno-Ajona D, Villar-Martínez MD, Goadsby PJ. Emerging Targets for Migraine Treatment. Neurol India [serial online] 2021 [cited 2021 Aug 1 ];69:98-104
Available from:;year=2021;volume=69;issue=7;spage=98;epage=104;aulast=Moreno-Ajona;type=0